WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317352
CAS#: 91714-93-1 (sodium)
Description: Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) marketed in the US as an ophthalmic solution by ISTA Pharmaceuticals for short-term, local use. Prolensa and Bromday are the once-daily formulation of bromfenac, while Xibrom was approved for twice-daily administration. Bromfenac is indicated for the treatment of ocular inflammation and pain after cataract surgery, though it may be prescribed in an off-label manner by the physician. The high degree of penetration and potency of bromfenac can be attributed to the halogenation of the molecule: by adding a bromine moiety the NSAID becomes highly lipophilic which allows for rapid, sustained drug levels in the ocular tissues.
MedKoo Cat#: 317352
Name: Bromfenac sodium
CAS#: 91714-93-1 (sodium)
Chemical Formula: C15H11BrNNaO3
Exact Mass: 333.00006
Molecular Weight: 356.1508
Elemental Analysis: C, 50.59; H, 3.11; Br, 22.44; N, 3.93; Na, 6.46; O, 13.48
Related CAS #: 91714-93-1 (sodium) 91714-94-2 (free acid).
Synonym: Bromfenac sodium, Prolensa, Bromday, Xibrom, AHR-10282, AHR10282, AHR 10282
IUPAC/Chemical Name: 2-Amino-3-(4-bromobenzoyl)benzeneacetic acid sodium
InChi Key: HZFGMQJYAFHESD-UHFFFAOYSA-M
InChi Code: InChI=1S/C15H12BrNO3.Na/c16-11-6-4-9(5-7-11)15(20)12-3-1-2-10(14(12)17)8-13(18)19;/h1-7H,8,17H2,(H,18,19);/q;+1/p-1
SMILES Code: O=C(O)CC1=CC=CC(C(C2=CC=C(Br)C=C2)=O)=C1N
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 356.1508 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Russo A, Morescalchi F, Vezzoli S, Bernini M, Turano R, Costagliola C, De
Ferrari F, Semeraro F. REDUCTION OF VITREOUS PROSTAGLANDIN E2 LEVELS AFTER
TOPICAL ADMINISTRATION OF INDOMETHACIN 0.5%, BROMFENAC 0.09%, AND NEPAFENAC 0.1.
Retina. 2015 Nov 11. [Epub ahead of print] PubMed PMID: 26562569.
2: Rodrigues EB, Farah ME, Mantovani Bottós J, Bom Aggio F. Nonsteroidal
Anti-Inflammatory Drugs in the Treatment of Retinal Diseases. Dev Ophthalmol.
2016;55:212-20. doi: 10.1159/000431197. Epub 2015 Oct 26. PubMed PMID: 26502088.
